SFS
CBAY

Sowell Financial Services’s Cymabay Therapeutics CBAY Stock Holding History

Sowell Financial Services’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,635
Closed -$7K – 2924
2021
Q1 		$7K Hold
1,635
– – ﹤0.01% 2491
2020
Q4 		$9K Hold
1,635
– – ﹤0.01% 2086
2020
Q3 		$12K Buy
1,635
+1,535
+1,535% +$8.21K ﹤0.01% 1767
2020
Q2 		$0 Buy
+100
New +$289 ﹤0.01% 2715

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sowell Financial Services's CBAY Position: Q2 2021 in Review

Sowell Financial Services sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 1,635 shares — an estimated $7K sold.

Sowell Financial Services first reported a position in CBAY in Q2 2020 and held it in 4 quarters. The position peaked at $12K in Q3 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • Sowell Financial Services reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 1,635 Cymabay Therapeutics shares in Q2 2021, an estimated $7K.
  • Sowell Financial Services first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 4 quarters.
  • Sowell Financial Services's Cymabay Therapeutics position peaked at $12K in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.